<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124734</url>
  </required_header>
  <id_info>
    <org_study_id>PSHCI 09-067</org_study_id>
    <nct_id>NCT01124734</nct_id>
  </id_info>
  <brief_title>High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma</brief_title>
  <official_title>Phase II Trial of High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have observed that many patients who had received high dose Interleukin-2
      (IL2) and failed to respond to it but who then go immediately to temozolomide seemed to enjoy
      extremely good responses which seem better quality and longer duration than typically
      observed for temozolomide alone. To date, the investigators have observed 5 sequentially
      treated patients with metastatic melanoma who had failed high dose IL-2 but who then went on
      to receive immediate temozolomide. Two of these patients had complete responses and 3 had
      very strong partial response. In a recent phase II study of extended low dose temozolomide
      alone given in the same manner as the post IL-2 patients noted above, the response rate was
      12.5% and all of these were partial responses only. The responses that the investigators
      observed were at a much higher rate of response as well as much better quality than expected
      for temozolomide. The responses were also better than those observed when temozolomide was
      given first and then followed by high dose IL-2. The investigators concluded that perhaps the
      major benefit the investigators observed was a result of the prior high dose IL-2 therapy
      modulated by the temozolomide and that the sequence of treatment was clearly crucial for this
      response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metastatic malignant melanoma remains a disease with a very poor prognosis and median
      survival duration of less than one year. Durable remissions with conventional therapy are
      rare and therefore clinical trials remain a primary treatment modality for metastatic
      disease. There are 2 currently FDA-approved therapies for metastatic melanoma. Chemotherapy
      with single agent parenteral dacarbazine or its oral pro-drug, temozolomide, are capable of
      producing responses in 6.5 to 20% of patients. These responses are usually minor to partial
      at best and are not durable. Combination with other chemotherapeutic drugs has not been
      successful. The immune system also seems to play a role in malignant melanoma. High dose
      Interferon therapy is the current standard therapy for the adjuvant treatment of stage IIB,
      IIC and III melanoma after surgical resection in which it has shown to result in modest
      improvements in disease free survival and overall survival. In metastatic disease, various
      immunologic approaches have been employed as well. High dose IL-2 can produce a response rate
      of about 10-15% in patients with metastatic melanoma. About 5-10% of responses are complete
      and some of these complete responses are durable so that the lucky few patients who have a
      durable complete response are for all intents and purposes cured. Attempts to combine
      chemotherapy with immunotherapy, although improving response rates, has not impacted survival
      as summarized in recent meta-analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 1, 2018</completion_date>
  <primary_completion_date type="Actual">July 18, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single group, open label study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response to High-Dose Interleukin-2 (H-D IL-2) Followed by Low Dose Temozolomide</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical response was measured using the Response Evaluation Criteria In Solid Tumors (RECIST) criteria categorizing responses as complete response (CR), partial response (PR), minor response (MR), stable disease (SD), or progressive disease (PD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response to High-Dose Interleukin-2 (H-D IL-2) Followed by Low Dose Temozolomide</measure>
    <time_frame>8 years</time_frame>
    <description>Duration of response is defined as the length (measured in days) from the date of best response to the date of progression (if any), or to the date of last follow-up (if no progression is observed). The duration of response is applicable for those CR/MR/PR/SD subjects only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Toxicity of H-D IL-2 Followed by Low Dose Temozolomide</measure>
    <time_frame>2 years</time_frame>
    <description>Safety and toxicity in this study population was evaluated using the NCI Common Toxicity Criteria. The unit of measure is the number of study participants with one or more unexpected and related (even remotely) SAE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of High Dose IL2 Followed by Low Dose Temozolomide on Lymphocyte Subsets (Autoimmune Biomarkers)</measure>
    <time_frame>2 years</time_frame>
    <description>The effect outcome is measured by the change in percentage of circulating lymphocyte cells (autoimmune biomarkers) that express the noted phenotype. This percentage change is determined by comparing the values obtained within 7 days of participant going off treatment against the baseline values.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Course 1 Cycle 1 and Cycle 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Course 1 Cycle 1: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals.
Course 1 Cycle 2: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals. On the day after discharge, patients will be given oral temozolomide at 75 mg/m2 daily for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg</description>
    <arm_group_label>Course 1 Cycle 1 and Cycle 2</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.</description>
    <arm_group_label>Course 1 Cycle 1 and Cycle 2</arm_group_label>
    <other_name>Temodar, Temodal, Temcad</other_name>
    <other_name>Temodal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed metastatic malignant melanoma

          -  Age &gt; 18 years

          -  Eastern Cooperative Oncology Group performance status of 0 or 1

          -  Patients considered good candidate for conventional high dose IL-2

          -  No chemotherapy, hormonal therapy, immunotherapy or radiation therapy within 1 month
             of entry

          -  Patients with a history or clinical evidence of brain metastasis must have completed
             radiation therapy or surgical treatment of brain lesions and have no evidence of
             central nervous system progression for at least 8 weeks at the time of enrollment.

          -  Patients may have had prior high dose IL-2 or temozolomide but not together or with
             high dose IL-2 followed by temozolomide

          -  Patients may have had prior high dose interferon as adjuvant treatment for high risk
             melanoma

          -  Serum creatinine &lt; 2 mg/dL

          -  Bilirubin &lt; 2 mg/dL

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Hypersensitivity to temozolomide or HD IL-2

          -  Active gastrointestinal disorder or cardiac disorders

          -  Ejection fraction &lt; 50% by echocardiogram or corrected diffusing capacity of lung for
             carbon monoxide &lt; 50% on diffusion capacity testing pulmonary function tests

          -  platelets &lt; 100 K, neutrophils &lt; 1000

          -  Serum Creatinine &lt; 2 x the upper limits of normal

          -  Chronic use of steroids other than for simple adrenal replacement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph J Drabick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2010</study_first_posted>
  <results_first_submitted>July 18, 2018</results_first_submitted>
  <results_first_submitted_qc>January 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2019</results_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Joseph Drabick</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Metastatic melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT01124734/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a single center study conducted at Penn State Hershey Medical Center Cancer Institute. The study was carried out in the Cancer Institute outpatient clinic. Accrual was initiated 9/07/2011 and completed completed 04/28/2014. Participants remained on study for long term follow up. The study closed in July 2018.</recruitment_details>
      <pre_assignment_details>Participants were excluded if they received any chemotherapy, hormonal therapy, immunotherapy, or radiation therapy within 1 month of entry to the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Course 1 Cycle 1 and Cycle 2</title>
          <description>This study is a single arm study. All participants received the same treatment regimen.
For initiation of study intervention (Course 1 – Cycle 1) participants are admitted inpatient for Course 1 Cycle 1 of HD IL-2 treatment. Participants will be given as many doses of IL-2 as tolerated up to a maximum of 14 at 8 hr intervals as allowed by the algorithm at 600,000 IU/kg. Participants will be discharged when the acute toxicities of the IL-2 have subsided.
Course 1 Cycle 2: After discharge, participants will be reassessed on or about 10 days after discharge (D10) and will be re-admitted to initiate Course 1 Cycle 2. For this Cycle 2, participants will be given as many doses of IL-2 as tolerated up to a maximum of 14 at 8 hr intervals as allowed by the algorithm at 600,000 IU/kg. After completion of this cycle 2 HD IL-2, they would begin Temzolomide at 75 mg/m2 on the day after hospital discharge. Participants will continue with Temzolomide for a total of 21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completion of Course 1 Cycle 1</title>
              <participants_list>
                <participants group_id="P1" count="17">All 17 participants successfully completed Course 1 Cycle 1</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Initiation of Course 1 Cycle 2</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Closed to accrual</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Elected for alternative treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants had melanoma.</population>
      <group_list>
        <group group_id="B1">
          <title>Course 1 Cycles 1 and 2</title>
          <description>Course 1 Cycles of Part 1: Participants will be given High-Dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals. Interleukin-2: up to a maximum of 14 doses at 600,000 IU/kg
Course 2: Patients will be given High-Dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals. On the day after discharge, patients will be given oral temozolomide at 75 mg/m2 daily for 21 days. Interleukin-2: up to a maximum of 14 doses at 600,000 IU/kg. Temozolomide: Patients would receive temozolomide at 75 mg/m2 after discharge from receipt of the second cycle of high dose IL-2. Patients would take the medication at bedtime daily. Four weeks after cycle 2 of a course, they would take it for 21 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Per NIH defined Racial and Ethnic Categories</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Region as defined by Country (i.e. United States, Canada, Vietnam, etc)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response to High-Dose Interleukin-2 (H-D IL-2) Followed by Low Dose Temozolomide</title>
        <description>Clinical response was measured using the Response Evaluation Criteria In Solid Tumors (RECIST) criteria categorizing responses as complete response (CR), partial response (PR), minor response (MR), stable disease (SD), or progressive disease (PD).</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Course 1 Cycle 1</title>
            <description>This study is a single arm study. All participants received the same treatment regimen.
Participants were given High-Dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals.
Interleukin-2: up to a maximum of 14 doses at 600,000 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Course 1 Cycle 2</title>
            <description>Patients will be given High-Dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals. On the day after discharge, patients will be given oral temozolomide at 75 mg/m2 daily for 21 days.
Interleukin-2: up to a maximum of 14 doses at 600,000 IU/kg
Temozolomide: Patients would receive temozolomide at 75 mg/m2 after discharge from receipt of the second cycle of high dose IL-2. Patients would take the medication at bedtime daily. Four weeks after cycle 2 of a course, they would take it for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response to High-Dose Interleukin-2 (H-D IL-2) Followed by Low Dose Temozolomide</title>
          <description>Clinical response was measured using the Response Evaluation Criteria In Solid Tumors (RECIST) criteria categorizing responses as complete response (CR), partial response (PR), minor response (MR), stable disease (SD), or progressive disease (PD).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minor Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Response to High-Dose Interleukin-2 (H-D IL-2) Followed by Low Dose Temozolomide</title>
        <description>Duration of response is defined as the length (measured in days) from the date of best response to the date of progression (if any), or to the date of last follow-up (if no progression is observed). The duration of response is applicable for those CR/MR/PR/SD subjects only.</description>
        <time_frame>8 years</time_frame>
        <population>Duration of response is applicable for those CR/MR/PR/SD subjects only.</population>
        <group_list>
          <group group_id="O1">
            <title>Course 1 Cycle 1 and Cycle 2</title>
            <description>This study is a single arm study. All participants received the same treatment regimen.
For initiation of study intervention (Course 1 – Cycle 1) participants are admitted inpatient for Course 1 Cycle 1 of HD IL-2 treatment. Participants will be given as many doses of IL-2 as tolerated up to a maximum of 14 at 8 hr intervals as allowed by the algorithm at 600,000 IU/kg. Participants will be discharged when the acute toxicities of the IL-2 have subsided.
Course 1 Cycle 2: After discharge, participants will be reassessed on or about 10 days after discharge (D10) and will be re-admitted to initiate Course 1 Cycle 2. For this Cycle 2, participants will be given as many doses of IL-2 as tolerated up to a maximum of 14 at 8 hr intervals as allowed by the algorithm at 600,000 IU/kg. After completion of this cycle 2 HD IL-2, they would begin Temzolomide at 75 mg/m2 on the day after hospital discharge. Participants will continue with Temzolomide for a total of 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response to High-Dose Interleukin-2 (H-D IL-2) Followed by Low Dose Temozolomide</title>
          <description>Duration of response is defined as the length (measured in days) from the date of best response to the date of progression (if any), or to the date of last follow-up (if no progression is observed). The duration of response is applicable for those CR/MR/PR/SD subjects only.</description>
          <population>Duration of response is applicable for those CR/MR/PR/SD subjects only.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="432.88" lower_limit="0" upper_limit="963.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Toxicity of H-D IL-2 Followed by Low Dose Temozolomide</title>
        <description>Safety and toxicity in this study population was evaluated using the NCI Common Toxicity Criteria. The unit of measure is the number of study participants with one or more unexpected and related (even remotely) SAE.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Course 1 Cycle 1</title>
            <description>This study is a single arm study. All participants received the same treatment regimen.
Participants were given High-Dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals.
Interleukin-2: up to a maximum of 14 doses at 600,000 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Course 1 Cycle 2</title>
            <description>Patients will be given High-Dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals. On the day after discharge, patients will be given oral temozolomide at 75 mg/m2 daily for 21 days.
Interleukin-2: up to a maximum of 14 doses at 600,000 IU/kg
Temozolomide: Patients would receive temozolomide at 75 mg/m2 after discharge from receipt of the second cycle of high dose IL-2. Patients would take the medication at bedtime daily. Four weeks after cycle 2 of a course, they would take it for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Toxicity of H-D IL-2 Followed by Low Dose Temozolomide</title>
          <description>Safety and toxicity in this study population was evaluated using the NCI Common Toxicity Criteria. The unit of measure is the number of study participants with one or more unexpected and related (even remotely) SAE.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of High Dose IL2 Followed by Low Dose Temozolomide on Lymphocyte Subsets (Autoimmune Biomarkers)</title>
        <description>The effect outcome is measured by the change in percentage of circulating lymphocyte cells (autoimmune biomarkers) that express the noted phenotype. This percentage change is determined by comparing the values obtained within 7 days of participant going off treatment against the baseline values.</description>
        <time_frame>2 years</time_frame>
        <population>Of the 17 qualifying participants, 9 underwent baseline (pre-Course 1) testing. Eleven participants consented to and underwent this POST off- treatment testing. Two of the participants tested at Post treatment did not have baseline testing done.</population>
        <group_list>
          <group group_id="O1">
            <title>% of Cells Expressing Phenotype Pre-treatment (BASELINE)</title>
            <description>% of lymphocyte subset cells (particularly the T-reg cells, on cytokine production and anti-melanoma specific t-cell immune cells) that express the particular phenotype noted. Measured at pre-treatment time period (i.e. baseline)</description>
          </group>
          <group group_id="O2">
            <title>% of Cells Expressing Phenotype Within 7 Days of Off-treatment</title>
            <description>% of lymphocyte subset cells (particularly the T-reg cells, on cytokine production and anti-melanoma specific t-cell immune cells) that express the particular phenotype noted. Measured within 7 days the participant went off treatment. Note: Off treatment day will vary by participant and response to treatment/other intervening factors (toxicity, withdrawal of IC, etc).</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of High Dose IL2 Followed by Low Dose Temozolomide on Lymphocyte Subsets (Autoimmune Biomarkers)</title>
          <description>The effect outcome is measured by the change in percentage of circulating lymphocyte cells (autoimmune biomarkers) that express the noted phenotype. This percentage change is determined by comparing the values obtained within 7 days of participant going off treatment against the baseline values.</description>
          <population>Of the 17 qualifying participants, 9 underwent baseline (pre-Course 1) testing. Eleven participants consented to and underwent this POST off- treatment testing. Two of the participants tested at Post treatment did not have baseline testing done.</population>
          <units>Percentage of Cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>%CCR7- CD45RO+ of CD4+ Effector Memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".36" spread=".10"/>
                    <measurement group_id="O2" value=".36" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%CCR7- CD45RO+ of CD8+ Effector Memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".31" spread=".10"/>
                    <measurement group_id="O2" value=".34" spread=".16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%CCR7- CD45RO- of CD4+ Effector Memory RA+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".09" spread=".08"/>
                    <measurement group_id="O2" value=".08" spread=".07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%CCR7- CD45RO- of CD8+ Effector Memory RA+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".46" spread=".18"/>
                    <measurement group_id="O2" value=".40" spread=".15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%CD25+FoxP3+ of CD4+ (Tregs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".10" spread=".05"/>
                    <measurement group_id="O2" value=".09" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for all AEs (Grade 0-V) from enrollment (signing consent) to the day they were rendered off study. The follow up period was indefinite as when off treatment, all were followed for disease status. Total time period for those who remained on study until the end is 8 years.</time_frame>
      <desc>Definition and processes the same as clinicaltrials.gov terminology.</desc>
      <group_list>
        <group group_id="E1">
          <title>Course 1 Cycle 1</title>
          <description>This study is a single arm study. All participants received the same treatment regimen.
Participants were given High-Dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals.
Interleukin-2: up to a maximum of 14 doses at 600,000 IU/kg</description>
        </group>
        <group group_id="E2">
          <title>Course 1 Cycle 2</title>
          <description>Patients will be given High-Dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals. On the day after discharge, patients will be given oral temozolomide at 75 mg/m2 daily for 21 days.
Interleukin-2: up to a maximum of 14 doses at 600,000 IU/kg
Temozolomide: Patients would receive temozolomide at 75 mg/m2 after discharge from receipt of the second cycle of high dose IL-2. Patients would take the medication at bedtime daily. Four weeks after cycle 2 of a course, they would take it for 21 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTC V4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>sinus tachycardia left bundle branch block</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTC V4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Anemia</description>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E2" events="12" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <description>Abdominal cramping</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Loss of Appetite - Anorexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increase</sub_title>
                <description>Alkaline phosphatase increase</description>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>Alanine aminotransferase increased</description>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <description>Aspartate aminotransferase increased</description>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Back pain</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased creatinine</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Capillary leak syndrome</sub_title>
                <description>Capillary leak syndrome</description>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="17"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Drabick, MD</name_or_title>
      <organization>Penn State Cancer Institute</organization>
      <phone>717 531 5059</phone>
      <email>jdrabick@pennstatehealth.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

